Chime Biologics Opens its European Innovation Hub in Basel, Switzerland and Launches the Chime Innovation Alliance
- Underscores Chime Biologics commitment to strengthening its presence in Europe and supporting Customers in this key market.
- Introducing the Chime Innovation Alliance, a fully integrated true one-stop solution that is now available to Customers facilitating cross-border market access and further collaboration between Europe and China.
- Chime Biologics to establish Advisory Board and grow the European Business Development team.
June 6, 2025, Basel, Switzerland – Chime Biologics, a leading global CDMO that enables its partners’ success in biologics, is pleased to announce the opening of its European Innovation Hub and launch of the Chime Innovation Alliance. The facility, located within the state-of-the-art Superlab Suisse’s Basel site, will provide Customers the opportunity to access early-stage development services for their biologic products, complementing our state-of-the-art development and manufacturing facilities in Shanghai and Wuhan, China.
Chime Biologics and its partners also proudly announced the establishment of the Chime Innovation Alliance. The Alliance, in collaboration with leading biotech service providers, aims to provide Customers the opportunity to access materials and services to support their end-to-end needs for pre-clinical, clinical or commercial biologics, from drug discovery to CMC development and clinical services. This Alliance will be showcased at our Innovation Hub in Basel, capitalizing on Basel’s reputation as a key biotech center in Europe and the world.
During the Office Opening Ceremony and Launch held today, representatives of Chime’s Customers, Management, Partners, Basel Area Business and Innovation and Chamber of Commerce engaged in a series of panel discussions focused on how initiatives such as the Chime Innovation Alliance will foster collaboration and partnership between Europe and China, providing the infrastructure for the development of high-quality, cost-effective biologics for patients. In addition, Chime Biologics announced the establishment of an Advisory Board consisting of seasoned industry experts that will guide Chime in further developing and growing its global CDMO capabilities and offering to Customers.
Dr. Jimmy Wei, President of Chime Biologics, highlighted, “We are thrilled to open Chime Biologics’ European Innovation Hub in Basel and launch the Chime Innovation Alliance, which reinforces our commitment to supporting Customers in Europe and our strategy of delivering high quality, cost effective and affordable biologics to customers and their patients worldwide. We look forward to working with our partners in demonstrating to the market our ability to provide a true end to end offering for their biologic.”
About Chime Biologics
Chime Biologics is a leading global CDMO, focused on ensuring its partners’ success in delivering innovative biologics to the world. Chime Biologics is a biologics service provider, from pre-clinical support and cell line development to clinical and commercial manufacturing of DS and DP. Employing our innovative and state-of-the-art development and manufacturing capabilities and proven success in supporting our clients with their clinical and commercial authorizations across the globe, Chime Biologics is a true end-to-end solution provider for the global biologics industry. We share a common goal to make cutting-edge biomedicines affordable and accessible to all patients globally, fulfilling our commitment to human health. For more information, please visit www.chimebiologics.com.
